UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading symbol(s) Name of each exchange on which registered N/A N/A N/A FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36385 BIOLASE, INC. (Exact name of registr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading symbol(s) Name of each exchange on which registered N/A N/A N/A FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36385 BIOLASE, INC. (Exact name of registrant a ...

Exhibit 99.1 BIOLASE REPORTS 2024 SECOND QUARTER RESULTS; ACHIEVES 40% GROSS MARGIN AS GLOBAL CONSUMABLE SALES STRENGTHEN LAKE FOREST, Calif., August 8, 2024 – BIOLASE, Inc. (NASDAQ: BIOL), a leader in dental laser technology, today reported its financial results for the second quarter ended June 30, 2024. "We experienced another strong quarter in consumable revenue, recording our second-highest mark ever and achieving over 600 recurring subscriptions," commented John Beaver, President and Chief Executive O ...

Company Participants Bruce Jackson - Benchmark Company Ed Woo - Ascendiant Capital Michael Polyviou Before we begin, I'd like to remind everyone that a number of forward-looking statements, which are any statements that are not historical facts will be made during this presentation and subsequent Q&A session, including forward-looking statements regarding the company's strategic initiatives and anticipated financial performance. These forward-looking statements are forward-looking statements as defined unde ...

SIGNATURES Title of each class Trading symbol(s) Name of each exchange on which registered ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 BIOLASE, INC. (Exact name of registrant as specified in its charter) BIOLASE, INC. | --- | --- | --- | |-----------------------|--------------------------------------------------------------------------------------------------------------------------|-------| | | | | | PART I. Item 1. ...

Exhibit 99.1 Full Year 2024 Financial Guidance BIOLASE REPORTS 2024 FIRST QUARTER RESULTS; REITERATES FULL-YEAR 2024 GUIDANCE FOR REVENUE GROWTH AND PROFITABILITY LAKE FOREST, Calif., May 13, 2024 – BIOLASE, Inc. (NASDAQ: BIOL), a leader in dental laser technology, today reported its financial results for the first quarter ended March 31, 2024. • Generated increased adoption of its industry-leading laser, with approximately 67% of U.S. Waterlase sales coming from new customers and approximately 42% from den ...

Nick Sherwood Awesome. Thank you for that detail. And then my next question is, what percentage of dentists who adopt your lasers continue to use your lasers as opposed to reverting back to traditional tools? What is that retention rate that you're seeing? John Beaver Yeah, so the most recent surveys we have, have our new doctors who have incorporated this technology in the last six to 12 months. User lasers, about -- I think it was about 90% of the doctors use it at least weekly, with a large percentage of ...

Security breaches of our information technology systems could harm our reputation and customer relationships. Such breaches could subject us to significant reputational, financial, legal, and operational consequences. Our revenue typically fluctuates from quarter to quarter due to a number of factors, many of which are beyond our control. Revenue in the first quarter typically is lower than average, and revenue in the fourth quarter typically is stronger than average due to the buying patterns of dental pra ...

Loading...Loading...The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.Here’s the latest list of maj ...

Expects Continued Revenue Growth in 2024 and Takes Steps to Further Improve Operating Efficiency as the Company Pursues Profitability Goals LAKE FOREST, Calif., Jan. 29, 2024 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced preliminary unaudited revenue results for 2023 based on currently available information and expects to report year-over-year growth as it continues to generate interest among dental practitioners for its industry leading lasers. The Company is a ...